top of page
Search

World’s First Approved Bispecific ADC Izalontamab Brengitecan Launches Clinical Use at Jiahui International Cancer Center

Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.


On July 16, 2026, NMPA granted Iza-Bren a new indication for recurrent or metastatic esophageal squamous cell carcinoma (ESCC) progressing after PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy (Application No. CXSS2600012). The approval is backed by the Phase 3 PANKU-Esophagus01 trial — the first global ADC study delivering positive dual PFS and OS endpoints for ESCC. It is poised to become the first standard ADC therapy for ESCC.


This launch marks a milestone where China’s biotech shifts from follower to global leader in precision oncology. Iza-Bren is now clinically available at the Cancer Center of Shanghai Jiahui International Hospital.

Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.

Unique Dual-Target ADC Design & Mechanism

Iza-Bren comprises three core components:

  1. Humanized EGFR×HER3 bispecific antibody: anti-EGFR IgG1 linked to anti-HER3 scFv via a GS linker;

  2. Cleavable Ac-GGFG linker;

  3. Topoisomerase I inhibitor payload Ed-04, with ~8 Brengitecan molecules conjugated per antibody unit.


The bispecific antibody binds EGFR and/or HER3 on tumor cell surfaces, enters cells via endocytosis, and releases Ed-04 after lysosomal enzymatic cleavage. The payload blocks tumor DNA synthesis to induce cancer cell death. Dual simultaneous target inhibition delivers broad anti-tumor coverage with superior precision, potency and stability.


Groundbreaking Clinical Efficacy Data

Phase 3 PANKU-NPC01 (Nasopharyngeal Carcinoma)

  • ORR: 54.6% vs chemotherapy 27.0% (double response rate)

  • Median DoR: 8.5 months vs 4.8 months

  • Median PFS: 8.38 months vs 4.34 months

    It has been listed as a preferred regimen by both NCCN and CSCO guidelines based on doubled survival benefits.


Phase 3 PANKU-Esophagus01 (ESCC, presented at 2026 ASCO Oral Session)

  • Median PFS: 4.17 months vs chemotherapy 1.97 months

  • Median OS: 9.79 months vs 7.20 months, 36% reduction in death risk (HR=0.64)

  • ORR: 35.3%, nearly triple chemotherapy’s 13.1%

  • DCR: 74.3% vs 45.5%

Iza-Bren demonstrates controllable safety and favorable tolerability: only 2.0% of patients discontinued treatment due to TRAEs (vs 3.3% chemotherapy), with ILD incidence as low as 1.6%.


Ongoing Clinical Exploration Across Multiple Tumors

Beyond NPC and ESCC, the New Drug Application for Iza-Bren in triple-negative breast cancer has been accepted by CDE under NMPA.


Comprehensive Pharmacy & Patient Services at Jiahui International Cancer Center

Our Cancer Center and Pharmacy Department rapidly introduce world-leading oncology therapies to expand treatment options for patients, with full-spectrum pharmaceutical services:

1. Drug Supply & Quality Management

Fully compliant with GSP standards for traceable procurement, storage and dispensing; supplies original international agents and high-quality generics for oncology and rare disease care.

2. Clinical Pharmacy Support

  • Pharmacists participate in MDT rounds to optimize regimens for complex cases;

  • Therapeutic Drug Monitoring (TDM) for personalized dosage adjustment of anti-infective and anti-tumor drugs;

  • 24-hour pre-prescription manual & digital review to standardize medication and reduce risks.

3. Full-Cycle Patient Medication Education

Dedicated consultation windows and online advisory channels; one-on-one bedside counseling for discharged patients, with intensive follow-up for first-time anti-tumor therapy users to ease anxiety and boost adherence.



Comments

Start My Medical Treatment

Gender
Preferred Chinese cities for Medical Treatment:
bottom of page